A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03657043 |
|
Recruitment Status :
Completed
First Posted : September 4, 2018
Results First Posted : May 6, 2023
Last Update Posted : May 6, 2023
|
Sponsor:
Seagen Inc.
Collaborator:
Genmab
Information provided by (Responsible Party):
Seagen Inc.
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
This trial will study tisotumab vedotin to find out what its side effects are and to see if it works for platinum-resistant ovarian cancer (PROC). It will test different doses of tisotumab vedotin that are given at different times. It will also compare the side effects and ability to treat tumors of these different doses and schedules. In this study, there will be a safety run-in group of approximately 12 patients that will look at a dose-dense treatment schedule. In a dose-dense schedule, smaller doses are given more frequently. In addition to the safety run-in patients, there will be three groups in the study. One group will get tisotumab vedotin once every 3 weeks (21-day cycles). The two other groups will get tisotumab vedotin once a week for 3 weeks followed by 1 week off (28-day cycles).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Ovarian Cancer Fallopian Tube Cancer Peritoneal Cancer | Drug: tisotumab vedotin | Phase 2 |
The study objectives are to evaluate the safety, antitumor activity, and pharmacokinetics of tisotumab vedotin (TV) administered every 3 weeks or on Days 1, 8, and 15 of every 4-week cycle (3Q4W) for patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has relapsed within 6 months of the completion of platinum-based treatment and determined to be platinum resistant. All patients must have PROC and be eligible for single agent chemotherapy.
The safety run-in period will evaluate the safety of a weekly schedule. The highest dose level that is considered safe will be the recommended phase 2 dose (RP2D) and will be used in Part A. In Part A, participants will be randomized in a 1:1 ratio to receive tisotumab vedotin intravenously (IV) every 3 weeks (Q3W regimen) or the safety run-in RP2D on Days 1, 8, and 15 of every 4-week cycle (weekly regimen; 3Q4W) if a RP2D has been identified. Participants who enroll in Part B will receive tisotumab vedotin on Days 1, 8, and 15 of every 4-week cycle (weekly regimen) at a pre-specified dose level, if the dose level is considered safe and tolerable in the safety run-in period.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 98 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen |
| Actual Study Start Date : | March 20, 2019 |
| Actual Primary Completion Date : | February 8, 2022 |
| Actual Study Completion Date : | February 8, 2022 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Ovarian cancer
Drug Information available for:
Tisotumab vedotin
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Safety Run-In (3Q4W Schedule)
28-day, 3 dose cycle
|
Drug: tisotumab vedotin
Intravenous (IV) infusion
Other Name: TIVDAK |
|
Experimental: Part A: Tisotumab Vedotin
21-day, single dose cycle
|
Drug: tisotumab vedotin
Intravenous (IV) infusion
Other Name: TIVDAK |
|
Experimental: Part A: Tisotumab Vedotin (3Q4W Schedule)
28-day, 3 dose cycle
|
Drug: tisotumab vedotin
Intravenous (IV) infusion
Other Name: TIVDAK |
|
Experimental: Part B: Tisotumab Vedotin (3Q4W Schedule)
28-day, 3 dose cycle
|
Drug: tisotumab vedotin
Intravenous (IV) infusion
Other Name: TIVDAK |
Primary Outcome Measures :
- Number of Participants With Dose-Limiting Toxicities (DLTs) (Safety Run-In Only) [ Time Frame: Up to 28 days ]Incidence of dose-limiting toxicity (DLT) was evaluated in participants enrolled in the Safety Run-In, who were followed for protocol-defined DLT events up to 28 days after the first dose of tisotumab vedotin.
- Confirmed Objective Response Rate (ORR) (Part B) [ Time Frame: Up to 9.7 months ]Proportion of participants who achieve a confirmed complete response (CR) or partial response (PR) according to RECIST v1.1 as assessed by the investigator
Secondary Outcome Measures :
- Number of Participants With Adverse Events (AEs) (Part B) [ Time Frame: Up to 23.0 months ]An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.
- Confirmed and Unconfirmed ORR (Part B) [ Time Frame: Up to 9.7 months ]Proportion of participants who achieve a CR or PR according to RECIST v1.1 as assessed by the investigator
- Cancer Antigen 125 (CA-125) Response Rate According to Gynecologic Cancer Intergroup (GCIG) Criteria (Part B) [ Time Frame: Up to 10.1 months ]Percentage of participants who have at least a 50% reduction in CA-125 value from baseline
- Overall Response According to the Gynecological Cancer Intergroup (GCIG) Combined RECIST and CA-125 Criteria (Part B) [ Time Frame: Up to 10.1 months ]Percentage of participants whose best response is a CR or PR according to the GCIG combined RECIST and CA-125 criteria
- Duration of Response (DOR) (Part B) [ Time Frame: Up to 8.3 months ]Time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the first documentation of PD or death due to any cause, whichever comes first
- Disease Control Rate (DCR) (Part B) [ Time Frame: Up to 3.0 months ]Percentage of participants who achieved a confirmed Complete Response(CR) or Partial Response (PR) per RECIST v1.1 as assessed by the investigator, or meet the Stable Disease (SD) criteria at least once after start of study treatment at a minimum interval of 12 weeks.
- Time to Response (TTR) (Part B) [ Time Frame: Up to 23.0 months ]Time from the start of study treatment to the first documentation of objective response (CR or PR that is subsequently confirmed)
- Progression-free Survival (PFS) (Part B) [ Time Frame: Up to 9.7 months ]Time from the start of study treatment to the first documentation of PD or death due to any cause, whichever comes first
- Overall Survival (OS) (Part B) [ Time Frame: Up to 23.0 months ]Time from the start of study treatment to date of death due to any cause
- Incidence of Antitherapeutic Antibodies (ATA) (Part B) [ Time Frame: Up to 6.9 months ]The proportion of participants who develop ATA at any time during the study. A positive baseline ATA result is considered positive post-baseline if the post-baseline ATA titer result is at least four times higher than the baseline result.
- Pharmacokinetic (PK) Parameter: Antibody-Drug Conjugate (ADC) Maximum Concentration (Cmax) (Part B) [ Time Frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle. ]ADC Cmax was derived from the PK blood samples collected.
- PK Parameter: ADC Time of Cmax (Tmax) (Part B) [ Time Frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle. ]ADC Tmax was derived from the PK blood samples collected.
- PK Parameter: ADC Area Under Concentration-Time Curve (AUC) (Part B) [ Time Frame: Cycle 1 Dose 1 AUC 7: Assessed from Cycle 1 Days 1 - 8 (predose). Cycle 1 Dose 3 AUC 7: Assessed from Cycle 1 Days 15 - 22. Cycle 1 Dose 3 AUC 14: Assessed from Cycle 1 Days 15 - Cycle 2 Day 1 (predose). ]ADC AUC was derived from the PK blood samples collected.
- PK Parameter: Free Monomethyl Auristatin E (MMAE) Cmax (Part B) [ Time Frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle. ]MMAE Cmax was derived from the PK blood samples collected.
- PK Parameter: MMAE Tmax (Part B) [ Time Frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle. ]MMAE Tmax was derived from the PK blood samples collected.
- PK Parameter: MMAE AUC (Part B) [ Time Frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle. ]MMAE AUC was derived from the PK blood samples collected.
- PK Parameter: MMAE Trough Concentration (Ctrough) (Part B) [ Time Frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle. ]MMAE Ctrough was derived from the PK blood samples collected.
- PK Parameter: Total Antibody (TAb) Cmax (Part B) [ Time Frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle. ]TAb Cmax was derived from the PK blood samples collected.
- PK Parameter: TAb Tmax (Part B) [ Time Frame: Samples for PK measures were collected at Cycle 1 Day 1 (predose, end of infusion, 1 hr, and 5 hr), Day 3, Day 8 (predose), Day 15 (predose, end of infusion, 1 hr, and 5 hr), Day 17, Day 22, and Cycle 2 Day 1 (predose). Approximately 4 weeks per cycle. ]TAb Tmax was derived from the PK blood samples collected.
- PK Parameter: TAb Area Under Concentration-Time Curve (AUC) (Part B) [ Time Frame: Cycle 1 Dose 1 AUC 7: Assessed from Cycle 1 Days 1 - 8 (predose). Cycle 1 Dose 3 AUC 7: Assessed from Cycle 1 Days 15 - 22. Cycle 1 Dose 3 AUC 14: Assessed from Cycle 1 Days 15 - Cycle 2 Day 1 (predose). ]TAb AUC was derived from the PK blood samples collected.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologic documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
- Safety run-in only: PROC. Patients may have received more than 1 prior systemic treatment regimen in the PROC setting.
-
Part A and Part B only: Patients with PROC who have received 1 to 3 anticancer lines of therapy overall, including at least 1 line of therapy containing bevacizumab or biosimilar.
- Adjuvant ± neoadjuvant are considered 1 line of therapy.
- Patients may have received a PARP inhibitor or an immuno-oncology (IO) agent; any of these regimens are to be considered a line of therapy for the purposes of this study if not used as maintenance therapy.
- Maintenance therapy (including bevacizumab, PARP inhibitors and IOs) will be considered part of the preceding line of therapy and not to be counted as a new line of therapy.
- Any chemotherapy regimen change due to toxicity in the absence of disease progression is considered as part of the same line of therapy.
- Hormonal therapy will be not be counted towards the lines of therapy.
- Measurable disease according to RECIST v1.1 as assessed by the investigator
- An Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
- Life expectancy of at least 3 months
- Able to provide fresh or archival tissue for biomarker analysis
Exclusion Criteria:
- Primary platinum-refractory disease, defined as disease progression within 2 months of completion of first line platinum-based therapy
- Patients with clinical symptoms or signs of gastrointestinal obstruction with the past 6 months or who currently require parenteral nutrition
- Hematological: Known past or current coagulation defects leading to an increased risk of bleeding, diffuse alveolar hemorrhage from vasculitis, known bleeding diathesis, ongoing major bleeding, or trauma with increased risk of life-threatening bleeding within 8 weeks of trial entry
- Cardiovascular: Clinically significant cardiac disease including uncontrolled hypertension, unstable angina, acute myocardial infarction with 6 months of screening, serious cardiac arrhythmia requiring medication, medical history of congestive heart failure, or medical history of decreased cardiac ejection fraction of <45%
- Ophthalmological: Active ocular surface disease at baseline or prior episode of cicatricial conjunctivitis or Stevens Johnson syndrome
- Prior treatment with MMAE-derived drugs
- Inflammatory bowel disease including Crohn's disease and ulcerative colitis
- Ongoing, acute, or chronic inflammatory skin disease
- Uncontrolled tumor-related pain
- Inflammatory lung disease requiring chronic medical therapy
- Grade 3 or higher pulmonary disease unrelated to underlying malignancy
- Uncontrolled pleural or pericardial effusions
- Grade >1 peripheral neuropathy
- Patients who are pregnant or breastfeeding
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03657043
Locations
Show 37 study locations
Sponsors and Collaborators
Seagen Inc.
Genmab
Investigators
| Study Director: | Kristi Schmidt, MD | Seagen Inc. |
Study Documents (Full-Text)
Documents provided by Seagen Inc.:
Documents provided by Seagen Inc.:
Study Protocol [PDF] August 24, 2020
Statistical Analysis Plan [PDF] February 12, 2021
| Responsible Party: | Seagen Inc. |
| ClinicalTrials.gov Identifier: | NCT03657043 |
| Other Study ID Numbers: |
SGNTV-002 |
| First Posted: | September 4, 2018 Key Record Dates |
| Results First Posted: | May 6, 2023 |
| Last Update Posted: | May 6, 2023 |
| Last Verified: | April 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Seagen Inc.:
|
Platinum-resistant Antibody drug conjugate Tisotumab vedotin PROC Seattle Genetics |
Additional relevant MeSH terms:
|
Ovarian Neoplasms Carcinoma, Ovarian Epithelial Fallopian Tube Neoplasms Endocrine Gland Neoplasms Neoplasms by Site Neoplasms Ovarian Diseases Adnexal Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases |
Genital Neoplasms, Female Urogenital Neoplasms Genital Diseases Endocrine System Diseases Gonadal Disorders Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Fallopian Tube Diseases Tisotumab vedotin Antineoplastic Agents, Immunological Antineoplastic Agents |